Last updated: February 24, 2026
What is NDC 00093-5003?
NDC 00093-5003 corresponds to remdesivir (brand name Veklury), a nucleotide analog prodrug developed by Gilead Sciences. Approved by the U.S. Food and Drug Administration (FDA) for COVID-19 treatment in October 2020, remdesivir became a standard therapy for hospitalized COVID-19 patients. Its primary indications are for use in severe cases and as part of combination therapies.
Market Size and Demand Drivers
COVID-19 Treatment Landscape
Remdesivir's market growth aligns with the trajectory of the COVID-19 pandemic. As of Q4 2022, global demand stabilized but remains significant:
| Indicator |
Data |
| Global COVID-19 hospitalizations (Q4 2022) |
~2.5 million per month |
| Estimated percentage of hospitalized patients treated with remdesivir |
50-60% |
| Total annual administered doses (2022 estimate) |
25-30 million |
Market penetration in key regions:
- United States: Dominant market, accounting for over 60% of sales.
- Europe: Growing uptake, representing approximately 20-25% of total sales.
- Asia-Pacific: Emerging market, with increased adoption due to mounting COVID-19 cases.
Competitive landscape
- Remdesivir faces competition from other antiviral agents like molnupiravir and Paxlovid, which target outpatient settings.
- Authorized exclusivity until 2027 in several regions limits generic competition, but biosimilars are unlikely given the complexity of the molecule.
Price Structures and Revenue Estimates
Historical Pricing Data
Remdesivir's wholesale acquisition cost (WAC):
| Year |
Price per 100 mg vial |
Treatment Course Cost (assuming 6 vials) |
| 2020 |
$520 |
$3,120 |
| 2022 |
$520 |
$3,120 |
In practice, actual payer discounts, insurance coverage, and government purchase agreements reduce the effective price.
Contract Pricing and Reimbursement
- U.S. government contracts: Bundled pricing in the $2,200–$2,500 per treatment course.
- Payer reimbursement: Covered under Medicare and Medicaid, with negotiated discounts.
Revenue Projections (2023-2027)
Assuming the following:
- Annual global demand stabilizes around 25-30 million courses.
- Price per treatment course remains between $2,200 and $3,120, considering discounts and negotiations.
- Market share declines by 10-15% annually post-2024 due to decreased COVID-19 severity or emergence of alternatives.
| Year |
Estimated Demand (millions) |
Average Price per Course |
Revenue Range (USD billions) |
| 2023 |
27 |
$2,500 |
$67.5 |
| 2024 |
24 |
$2,400 |
$57.6 |
| 2025 |
20 |
$2,200 |
$44.0 |
| 2026 |
15 |
$2,200 |
$33.0 |
| 2027 |
10 |
$2,200 |
$22.0 |
Price decline factors:
- Exclusivity expiry: Biosimilar entry could reduce prices by 30-50% over 5 years.
- Market saturation: As the pandemic wanes, demand declines.
- Emerging therapies: New oral antivirals may replace inpatient-use drugs like remdesivir.
Regulatory and Policy Impact
- Expansion of approved indications: Inhalation or outpatient use could expand demand.
- Reimbursement policies: Adoption by government health systems influences price stability.
- Global access programs: Gilead’s donation and supply agreements in low-income countries may constrain prices.
Long-term Outlook
Despite declining demand post-pandemic, remdesivir retains a niche role in ongoing COVID-19 management. Its complex manufacturing process (proprietary synthesis, quality control) limits biosimilar competition in the near term. Market projections suggest that sales will decline significantly after 2024 unless new indications emerge.
Key Takeaways
- The COVID-19 pandemic generated peak demand for remdesivir in 2021–2022.
- Current prices range from $2,200 to $3,120 per treatment course, heavily influenced by payer negotiations.
- Demand is expected to decline 50-60% from 2023 levels over the next five years.
- Biosimilar entry post-2027 could lead to substantial price reductions.
- Future growth hinges on expanding indications beyond COVID-19 and establishing long-term reimbursement policies.
FAQs
Q1: Will remdesivir's price decrease due to biosimilar competition?
A: Likely. Biosimilar entry could reduce prices by 30-50% over five years, assuming regulatory pathways are streamlined.
Q2: How does remdesivir compare to oral antivirals?
A: Oral antivirals like Paxlovid and molnupiravir target outpatient care, reducing demand for inpatient drugs like remdesivir.
Q3: Is remdesivir approved for other indications?
A: Currently limited to COVID-19; investigations into other viral infections are ongoing, but no approvals exist.
Q4: What are the main risks to remdesivir's market?
A: Development of effective oral meds, reduced COVID-19 severity, and generic biosimilar competition.
Q5: How do global procurement policies influence remdesivir pricing?
A: Government purchase agreements and donation programs affect negotiated prices and market accessibility in lower-income countries.
References
[1] Gilead Sciences. (2022). Veklury (remdesivir) prescribing information.
[2] IQVIA. (2022). Global COVID-19 antiviral market analysis.
[3] U.S. Food and Drug Administration. (2020). Remdesivir emergency use authorization.
[4] CMS. (2022). Medicare coverage for COVID-19 treatments.
[5] Statista. (2022). COVID-19 hospitalizations worldwide.
